Amylin Pharmaceuticals Reports Narrower-Than-Expected Loss (AMLN)

4-26-12-Amylin Pharmaceuticals (NASDAQ:AMLN) reported a Q1 loss of $0.23, topping estimates by $0.04.Revenues in the quarter were flat at $153.7 million, missing estimates by $8 million.Amylin Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, develops, and commercializes medicines for diabetes and obesity. The Company’s marketed products include treatments for adults with type 1 and type 2 diabetes.